Specialty Pharmacies

The XOLAIR® Specialty Pharmacy Network is a group of specialty pharmacies that have been selected to provide XOLAIR (Omalizumab) for Subcutaneous Use coverage and reimbursement support and to dispense XOLAIR to health care providers for their patients (see How to Enroll for details). Genentech works with these top specialty pharmacies to provide outstanding patient and clinical support to XOLAIR patients and prescribers.

Specialty pharmacies are uniquely positioned to provide a comprehensive array of services for patients with chronic diseases that often require complex reimbursement support and ongoing clinical support services. Some of the many services provided by specialty pharmacies are:

  • Coverage and reimbursement resources for the complicated paperwork and complex payer landscape
  • Support to help patients understand and successfully manage complex medication processes
  • Clinical services to support patients throughout their therapies, such as compliance and persistency programs and nursing services
  • Ability to manage special handling and shipping requirements associated with many specialty pharmacy therapies

The XOLAIR Specialty Pharmacy Network is made up of the following pharmacies:

Accredo Nova Factor, Inc. (click here for more information)
Phone: (866) 839-2162
Fax: (866) 531-1025
Website: www.novafactor.com

Caremark Rx, Inc. (click here for more information)
Phone: (800) 237-2767
Fax: (800) 323-2445
Website: www.caremark.com

CuraScript Inc. (click here for more information)
Phone: (888) 281-5464
Fax: (888) 773-7386
Website: www.curascript.com

OptionCare, Inc. (click here for more information)
Phone: (888) 282-5166
Fax: (888) 570-4700
Website: www.optioncare.com

XOLAIR (Omalizumab) for Subcutaneous Use Indication

XOLAIR is indicated for adults and adolescents (12 years of age and older) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with ICS. XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions.

WARNING

Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, patients should be closely observed for an appropriate period of time after XOLAIR administration, and health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Patients should also be informed of the signs and symptoms of anaphylaxis and instructed to seek immediate medical care should symptoms occur (see WARNINGS, and PRECAUTIONS, Information for Patients).

XOLAIR Safety Information

  • XOLAIR should only be administered in a health care setting by health care providers prepared to manage anaphylaxis that can be life- threatening.
  • XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR (see Boxed WARNING). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction.
  • Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR- treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders.
  • Patients should be given and instructed to read the Medication Guide before starting treatment and before each subsequent treatment.
  • Patients receiving XOLAIR should be told not to decrease the dose of, or stop taking any other asthma medications unless otherwise instructed by their physician.
  • The adverse reactions most commonly observed among patients treated with XOLAIR in clinical studies included injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.

Please note: This website contains links to a number of other sites that may offer useful information. We suggest visiting those sites directly to obtain information on specific details of coverage as well as educational and financial support services for XOLAIR® (Omalizumab). Genentech, Inc. and Novartis Pharmaceuticals Corporation are not partners with or affiliated with any company listed. The availability of health insurance coverage and financial assistance varies from company to company, plan to plan and state to state. Genentech, Inc. and Novartis Pharmaceuticals Corporation do not imply or guarantee that a specific health insurance plan or any other company will provide coverage or assistance for XOLAIR. Genentech, Inc. and Novartis Pharmaceuticals Corporation are not responsible for any decisions regarding partial or non-coverage of XOLAIR.

support line